Thomson Reuters, a US-based provider of information for businesses and professionals, has announced that the National Cancer Institute (NCI) has joined the community of scientists worldwide using BIOMARKERcenter, a unique comprehensive resource for biomarker intelligence. The National Cancer Institute (NCI) is a component of the National Institutes of Health (NIH), one of eight agencies that compose the Public Health Service (PHS) in the Department of Health and Human Services (DHHS).
BIOMARKERcenter is claimed to be the first comprehensive resource to provide pharmaceutical, biotechnology, diagnostic, and research organisations with a framework for assessing and tracking a potential biomarker for use at any stage of research or development. Specifically, the National Cancer Institute's Developmental Therapeutics programme and the associated Biomarker Programme will integrate BIOMARKERcenter into its continuing efforts to investigate novel chemical and biological agents for their potential to improve cancer therapeutics.
BIOMARKERcenter covers the biomarkers identified in literature, patents, conferences, clinical trial information, and other sources for all major therapeutic areas including oncology, cardiovascular diseases, diabetes, respiratory disorders, autoimmune diseases and neurological disorders. For each therapy area, it includes not only biomarkers with established clinical usage, but also emerging uses for the biomarker.
Each record is manually curated and expertly indexed to allow searching by fields such as name, type, biological process, indication, population, role, measurement technique, substrate, lifecycle stage, and development status of diagnostic kits. Each record is further enriched with links to all supporting source documents, throughout the history of the biomarker.
